Alexandria T. Phan - Concepedia

Author

Alexandria T. Phan

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

A Phan, A T Phan, A. Phan, A. T. Phan, A.T. Phan, ALEXANDRIA T. PHAN, Alexandria Phan, Alexandria T Phan, Alexandria T. Phan, Alexandria T. Phan, MD, FACP

236

Publications

14.9K

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Methodist Hospital Ipsen (France)Charité - Universitätsmedizin Berlin Ipsen (United States)

About

Alexandria T. Phan is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	23	43	3.1K
2	Health Sciences	10	10	809
3	Public Health	3	3	339
4	Cell Biology	2	2	28
5	Biochemistry	1	1	81

Alexandria T. Phan

Publications

9.9K

Citations

H-Index

Page 1

	Year	Citations
Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors Martyn Caplin, Marianne Pavel, Jarosław B. Ćwikła, New England Journal of Medicine	2014	1.9K
Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II Study James C. Yao, Alexandria T. Phan, David Z. Chang, Journal of Clinical Oncology	2008	645
Consensus Guidelines for the Management and Treatment of Neuroendocrine Tumors Pamela L. Kunz, Diane Reidy‐Lagunes, Lowell Anthony, Pancreas Tumor BiologyGliomaMedicineNeuroendocrine DisorderPathology	2013	582
Clinical Risk Factors for Malignancy and Overall Survival in Patients with Pheochromocytomas and Sympathetic Paragangliomas: Primary Tumor Size and Primary Tumor Location as Prognostic Indicators Montserrat Ayala‐Ramirez, Lei Feng, Marcella M. Johnson, The Journal of Clinical Endocrinology & Metabolism	2010	419
Targeting Vascular Endothelial Growth Factor in Advanced Carcinoid Tumor: A Random Assignment Phase II Study of Depot Octreotide With Bevacizumab and Pegylated Interferon Alfa-2b James C. Yao, Alexandria T. Phan, Paulo M. Hoff, Journal of Clinical Oncology	2008	410
The NANETS Consensus Guidelines for the Diagnosis and Management of Poorly Differentiated (High-Grade) Extrapulmonary Neuroendocrine Carcinomas Jonathan Strosberg, Domenico Coppola, David S. Klimstra, Pancreas Surgical OncologyExpress SomatostatinPathologySecretory Hormonal SyndromesNeuro-oncology	2010	348
Population-Based Study of Islet Cell Carcinoma James C. Yao, Milton P. Eisner, Colleen Leary, Annals of Surgical Oncology	2007	337
Reduction of Cancer-Related Fatigue With Dexamethasone: A Double-Blind, Randomized, Placebo-Controlled Trial in Patients With Advanced Cancer Sriram Yennurajalingam, Susan Frisbee‐Hume, J. Lynn Palmer, Journal of Clinical Oncology	2013	334
Mylotarg? (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation Francis J. Giles, H. Kantarjian, Steve Kornblau, Cancer	2001	280
Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study Martyn Caplin, Marianne Pavel, Jarosław B. Ćwikła, Endocrine Related Cancer	2016	233

Page 1